Phase 1 Study of IACS-010759 in Subjects with relapsed or refractory AML
This clinical research study has 2 parts: dose escalation and dose expansion. The goal of dose escalation in this clinical research study is to find the best dose of IACS-010759 that can be given to patients with relapsed or refractory AML. The goal of dose expansion in this clinical research study is to learn if the dose of IACS-010759 found in the dose escalation part of the study is the best dose to use in future studies using IACS-010759 in patients with AML. The safety and tolerability of this drug will also be studied. This is the first study using IACS-010759 in humans.
Treatment Location: N/A
IRB Review and Approval Date: 09/29/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: